Jeppesen PB, et al. - Because disease-associated factors influence parenteral support (PS) reduction in response to teduglutide, an analog of the intestinotrophic hormone glucagon-like peptide-2, in patients with intestinal failure associated-short bowel syndrome (SBS–IF), researchers analyzed correlative links between plasma citrulline levels, small bowel length, and PS volume. Individuals treated with teduglutide displayed numerically greater increases in plasma citrulline at Week 24 compared with placebo in all subgroups. Analysis of 24 weeks of teduglutide treatment from a randomized controlled study demonstrated significant associations of baseline plasma citrulline with small bowel length in patients with ≥ 50% colon remaining/no stoma/colon-in-continuity, and patients with SBS–IF causes other than IBD/vascular disease. Citrulline levels that correlate with changes in PS in teduglutide response and further studies may exhibit a correlation between citrulline levels in the heterogeneous population of SBS−IF patients.